257 related articles for article (PubMed ID: 12638211)
21. Bisphosphonates and primary hyperparathyroidism.
Rodan GA
J Bone Miner Res; 2002 Nov; 17 Suppl 2():N150-3. PubMed ID: 12412793
[TBL] [Abstract][Full Text] [Related]
22. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
23. From bathtub ring to osteoporosis: a clinical review of the bisphosphonates.
Licata AA
Cleve Clin J Med; 1993; 60(4):284-90. PubMed ID: 8339454
[TBL] [Abstract][Full Text] [Related]
24. [Bisphosphonates in the treatment of multiple myeloma].
Stajszczyk M
Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
[TBL] [Abstract][Full Text] [Related]
25. [Bisphosphonates: pharmacology and use in the treatment of osteoporosis].
Kishimoto H
Nihon Rinsho; 1998 Jun; 56(6):1531-6. PubMed ID: 9648477
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological therapy of Paget's and other metabolic bone diseases.
Hosking D
Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
[TBL] [Abstract][Full Text] [Related]
27. [Bisphosphonates. A neu therapy principle in calcium and bone metabolism disorders].
Raue F
Internist (Berl); 1999 Apr; 40(4):448-55. PubMed ID: 10354947
[No Abstract] [Full Text] [Related]
28. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY
Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of action of bisphosphonates.
Rodan GA
Annu Rev Pharmacol Toxicol; 1998; 38():375-88. PubMed ID: 9597160
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates: preclinical aspects and use in osteoporosis.
Fleisch HA
Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
[TBL] [Abstract][Full Text] [Related]
31. Paget disease of bone: therapeutic options.
Silverman SL
J Clin Rheumatol; 2008 Oct; 14(5):299-305. PubMed ID: 18838910
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of action of the bisphosphonates.
Fleisch H
Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
[TBL] [Abstract][Full Text] [Related]
33. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
34. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
Leu CT; Luegmayr E; Freedman LP; Rodan GA; Reszka AA
Bone; 2006 May; 38(5):628-36. PubMed ID: 16185944
[TBL] [Abstract][Full Text] [Related]
35. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Fitton A; McTavish D
Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854
[TBL] [Abstract][Full Text] [Related]
36. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
[TBL] [Abstract][Full Text] [Related]
37. The therapeutic use of bisphosphonates.
Compston JE
BMJ; 1994 Sep; 309(6956):711-5. PubMed ID: 7950525
[No Abstract] [Full Text] [Related]
38. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
Hodsman A; Adachi J; Olszynski W
CMAJ; 1996 Oct; 155(7):945-8. PubMed ID: 8837544
[TBL] [Abstract][Full Text] [Related]
39. Clinical effects of bisphosphonates in involutional osteoporosis.
Ott SM
J Bone Miner Res; 1993 Dec; 8 Suppl 2():S597-606. PubMed ID: 8122531
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
Kanakis I; Kousidou OCh; Karamanos NK
In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
